# Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

> **NCT01450761** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1351 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Placebo matching Ipilimumab
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01450761
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-13
- **Primary completion:** 2015-03-19
- **Final completion:** 2017-05-17
- **Target enrollment:** 1351 (ACTUAL)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01450761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01450761, "Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01450761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*